# US 2022/0033473 A1 · COMPOSITION COMPRISING RECOMBINANT GpIba RECEPTOR PROTEIN

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033473 A1
- Document ID: US20220033473A1
- Status: Published application
- Kind: A1
- Application number: 16/479,068
- Filed: 2019-02-15
- Published: 2022-02-03
- Earliest claimed: 2018-02-20
- Assignees: Grifols Diagnostic Solutions Inc.
- Applicants: Grifols Diagnostic Solutions Inc.
- Inventors: Elizabeth Booth; Virginia Montanini; John A. Hall; Jody Berry
- Web page: https://patentgrep.com/patent/US20220033473A1

## CPC

- C07K 14/745: Blood coagulation or fibrinolysis factors
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/21: containing a His-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G01N 2333/755: Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ibα that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.

## Claims

### Claim 1

A recombinant polypeptide that specifically binds human von Willebrand Factor, comprising a modified extracellular domain of platelet glycoprotein Ibα, wherein:
the recombinant polypeptide lacks a transmembrane domain; and
the modified extracellular domain comprises at least one mutation selected from G233T, D235V, and K237V, relative to SEQ ID NO: 19.

### Claim 2 (depends on 1)

The recombinant polypeptide of claim 1, wherein the recombinant polypeptide has a higher binding affinity for the von Willebrand Factor of a human blood sample or human blood plasma sample than a control polypeptide that does not comprise the at least one mutation but that is otherwise identical to the recombinant polypeptide.

### Claim 3 (depends on 1)

The recombinant polypeptide of claim 1, wherein the Kd of the recombinant polypeptide and human von Willebrand Factor is less than 1 μM, 750 nM, 500 nM, 250 nM, or 100 nM.

### Claim 4 (depends on 1)

The recombinant polypeptide of claim 1, wherein the modified extracellular domain comprises:
mutations C65S and G233T;
mutations C65S and D235V;
mutations C65S and K237V; or
mutations C65S, G233T, and M239T, relative to SEQ ID NO: 19.

### Claim 5 (depends on 1)

The recombinant polypeptide of claim 1, wherein the modified extracellular domain has at least about 95% sequence identity with at least about 250 consecutive amino acids of an amino acid sequence selected from the group consisting of: SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; and SEQ ID NO: 5.

### Claim 6 (depends on 5)

The recombinant polypeptide of claim 5, wherein the modified extracellular domain comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; and SEQ ID NO: 5.

### Claim 7 (depends on 1)

The recombinant polypeptide of claim 1, further comprising a cross-linking domain, wherein the cross-linking domain comprises one or more of the group consisting of: a C-terminal cysteine, a negatively-charged C-terminal domain, and streptavidin binding protein.

### Claim 8 (depends on 7)

The recombinant polypeptide of claim 7, wherein the amino acid sequence of the cross-linking domain is selected from the group consisting of: SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 16; SEQ ID NO: 17; and SEQ ID NO: 18.

### Claim 9 (depends on 1)

The recombinant polypeptide of claim 1, further comprising an affinity tag selected from the group consisting of: polyhistidine tag, Snap tag, Clip tag, HaloTag, SnoopTag, SpyTag, chitin binding protein, maltose binding protein, Strep-tag, glutathione-S-transferase, FLAG-tag, V5-tag, Myc-tag, HA-tag, NE-tag, AviTag, Calmodulin-tag, polyglutamate, S-tag, SBP-tag, Softag 1, Softag 3, TC tag, VSV-tag, Xpress tag, Isopeptag, biotin carboxyl carrier protein, green fluorescent protein-tag, Nus-tag, thioredoxin-tag and the Fc domain of an antibody.

### Claim 10 (depends on 9)

The recombinant polypeptide of claim 9, wherein the affinity tag is a polyhistidine tag having from 6 to 8 histidine residues.

### Claim 11 (depends on 9)

The recombinant polypeptide of claim 9, wherein the amino acid sequence of the affinity tag is selected from the group consisting of SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 43, SEQ ID NO: 44; SEQ ID NO: 45; OF and SEQ ID NO: 46.

### Claim 12 (depends on 1)

The recombinant polypeptide of claim 1, further comprising an oligomerization domain, wherein the oligomerization domain is capable of forming a dimer, trimer, tetramer, or pentamer.

### Claim 13 (depends on 12)

The recombinant polypeptide of claim 12, wherein the oligomerization domain is selected from the group consisting of p53, GCN4, clathrin, pent-tag, or the Fc domain of an antibody.

### Claim 14 (depends on 12)

The recombinant polypeptide of claim 12, wherein the amino acid sequence of the oligomerization domain is selected from the group consisting of SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; and SEQ ID NO: 46.

### Claim 15 (depends on 1)

The recombinant polypeptide of claim 1, wherein the amino acid sequence of the recombinant polypeptide has at least about 95% sequence identity with an amino acid sequence selected from the group consisting of: SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 33; SEQ ID NO: 39; SEQ ID NO: 40; and SEQ ID NO: 41.

### Claim 16 (depends on 1)

The recombinant polypeptide of claim 1, wherein the amino acid sequence of the recombinant polypeptide is selected from the group consisting of: SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 33; SEQ ID NO: 39; SEQ ID NO: 40; and SEQ ID NO: 41.

### Claim 17

A recombinant polypeptide that specifically binds human von Willebrand Factor, comprising a modified extracellular domain of platelet glycoprotein Ibα, wherein:
the modified extracellular domain comprises mutations C65A, G233V and M239V, relative to SEQ ID NO: 19.

### Claim 18 (depends on 17)

The recombinant polypeptide of claim 17, wherein the amino acid sequence of the modified extracellular domain comprises the amino acid sequence of SEQ ID NO: 42 or wherein the amino acid sequence of the recombinant polypeptide is selected from the group consisting of: SEQ ID NO: 26; SEQ ID NO: 27; and SEQ ID NO: 28.

### Claim 19

A recombinant polypeptide that specifically binds human von Willebrand Factor, comprising a modified extracellular domain of platelet glycoprotein Ibα, wherein:
the modified extracellular domain comprises:
the A238V mutation; or
the Δ(229-240) mutation, relative to SEQ ID NO: 19; and
the recombinant polypeptide has a lower binding affinity for von Willebrand Factor of a human blood or a human blood plasma sample than a control polypeptide that does not comprise the A238V mutation or the Δ(229-240) mutation but that is otherwise identical to the recombinant polypeptide.

### Claim 20 (depends on 19)

The recombinant polypeptide of claim 19, wherein the amino acid sequence of the modified extracellular domain comprises the amino acid sequence set forth in of SEQ ID NO: 6 or SEQ ID NO: 9, or wherein the amino acid sequence of the recombinant polypeptide is SEQ ID NO: 36 or SEQ ID NO: 38.

### Claim 21 (depends on 1)

The recombinant polypeptide of claim 1, further comprising a leader peptide.

### Claim 22 (depends on 21)

The recombinant polypeptide of claim 21, wherein the amino acid sequence of the leader peptide is SEQ ID NO: 20.

### Claim 23 (depends on 1)

An oligomeric polypeptide, comprising at least two of the recombinant polypeptides according to claim 1.

### Claim 24 (depends on 1)

A cell, comprising the recombinant polypeptide of claim 1.

### Claim 25 (depends on 24)

The cell of claim 24, wherein the cell is a CHO, HEK, BHK, NS0, Sp2/0, COS, C127, HT-1080, PER.C6, HeLa, or Jurkat cell.

### Claim 26 (depends on 1)

A nucleic acid, comprising:
a nucleotide sequence encoding the recombinant polypeptide of claim 1; and
a promoter operably linked to the nucleotide sequence.

### Claim 27 (depends on 26)

A cell, comprising the nucleic acid of claim 26.

### Claim 28 (depends on 1)

A composition, comprising the recombinant polypeptide of claim 1, and a solid support, wherein the recombinant polypeptide or the oligomeric polypeptide is covalently or non-covalently bound to the solid support.

### Claim 29 (depends on 28)

The composition of claim 28, wherein the solid support comprises a particle, a bead, a membrane, a surface, a polypeptide chip, a microtiter plate, or the solid-phase of a chromatography column.

### Claim 30 (depends on 29)

The composition of claim 29, wherein the solid support is a latex particle.

### Claim 31 (depends on 28)

The composition of claim 28, further comprising von Willebrand Factor.

### Claim 32 (depends on 31)

The composition of claim 31, wherein:
the solid support comprises a plurality of particles or beads; and
the von Willebrand Factor cross-links the particles or beads of the plurality of particles or beads.

### Claim 33 (depends on 31)

The composition of claim 31, further comprising human blood plasma.

### Claim 34 (depends on 33)

The composition of claim 33, further comprising human platelets.
